Safety Mexidol® (ethylmethylhydroxypyridine of succinate) in adult patients of different age groups

Authors:
E.A. USHKALOVA¹, S.K. ZYRYANOV^1,2, O.I. BUTRANOVA¹

¹Federal State Autonomous Educational Institution of Higher Education “Peoples’ Friendship University of Russia”
²State Budgetary Healthcare Institution “City Clinical Hospital No. 24 of the Moscow City Health Department”

Place of publication:
NEUROLOGY, NEUROPSYCHIATRY, PSYCHOSOMATICS. 2022

Abstract:
To reduce the risk of adverse events and improve treatment adherence in elderly patients, it is recommended to minimize the total number of prescribed medications, if possible using a single medication to treat two or more conditions. Medications that meet the criteria for use in elderly patients and/or patients with comorbidities include the original Russian drug Mexidol®⁽ ethylmethylhydroxypyridine succinate), which has a multimodal mechanism of action and produces multiple pharmacological effects. In order to study the safety of Mexidol in comparison with placebo in patients with chronic cerebral ischemia of different age groups, a post-hoc analysis of the international multicenter, randomized, double-blind, placebo-controlled MEMO study with an adaptive design was conducted to evaluate the efficacy and safety of sequential therapy with Mexidol^® solution for intravenous and intramuscular administration, 50 mg / ml (OOO NPK PHARMASOFT, Russia) and Mexidol^® FORTE 250 film-coated tablets, 250 mg (OOO NPK PHARMASOFT, Russia) in patients with chronic cerebral ischemia) involving 318 patients aged 40 to 90 years. Comparable safety and tolerability of Mexidol in middle-aged and elderly individuals with chronic cerebral ischemia, including patients over 75 years of age, was demonstrated. Key words: adult patients of different age groups; elderly; MEMO study; Mexidol^®; Mexidol^® FORTE 250; ethylmethylhydroxypyridine succinate; safety.